A portfolio of high quality, innovative companies
Portfolio
T-Cypher Bio
At T-Cypher Bio we generate TCR-based therapeutics that have the potential to transform the treatment of solid tumours, autoimmune, inflammatory, and infectious diseases.
T-Cypher Bio Website
Function RX
Function RX is a company developing therapies for neurodegeneration.
Function RX Website
Affect Therapeutics
Affect Therapeutics is a team of passionate people who are changing the way the world treats addiction.
Affect Therapeutics Website
HillStar Bio
Hillstar aspires to build a portfolio of programs against autoimmune diseases with unmet or underserved medical needs. Its lead program is an antibody designed to selectively target a root cause of Cold Agglutinin Disease (CAD) and Systemic Lupus Erythematosus (SLE).
HillStar Bio Website
OZLO Sleep
Better sleep streams here. Meet the next-gen streaming Sleepbuds® you've been dreaming about. These tiny, exceptionally comfortable wireless headphones have been specifically designed for all-night comfort, so you can sleep soundly. Sleepbuds® have been clinically validated to help you fall asleep. With biometric sensors for insights about your sleep and results-driven solutions.
OZLO Sleep Website
Caldan Therapeutics
Developing activators of free fatty acid receptors to treat metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH)
Caldan Therapeutics Website
Eliem Therapeutics
Developing ETX-810 to treat chronic pain, and ETX-155, to treat major depressive disorder, perimenopausal depression and focal onset seizures. LifeArc invested alongside RA Capital, Intermediate Capital Group, Access Biotechnology, Samlyn Capital and Acorn Bioventures in a $60 million Series B financing in May 2021.
Eliem Therapeutics Website
Maxion Therapeutics
Maxion Therapeutics Website
RQ BIO
RQ BIO Website
AviadoBio
Developing transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders
AviadoBio Website
Pheno Therapeutics
Discovering and developing small molecules to promote remyelination to treat multiple sclerosis
Pheno Therapeutics Website
Ikarovec
Developing novel, differentiated gene therapies for eye conditions, including diabetic macular oedema, age-related macular degeneration (AMD) and intra-ocular hypertension
Ikarovec Website
Cumulus Neuroscience
Their next-generation integrated physiological and digital biomarker platform can monitor diseases of the central nervous system at home – providing feedback on disease progression and response to treatment
Cumulus Neuroscience Website
Closed Loop Medicines
Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
Closed Loop Medicines Website
Surgery Hero
Surgery Hero is a virtual program that helps people prepare their mind and body for surgery through sustainable lifestyle changes.
Surgery Hero Website
As a specialty life sciences investor, LifeArc’s sector expertise and focused network provide us with significant competitive advantages today – and insights that are strategically critical for our continued growth into the future.
LifeArc had the vision to support RQ Bio from the very beginning and as a direct result new innovative antibodies were discovered to potentially protect vulnerable patients from Covid. In addition, a company was also born that will develop medicines to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from a multitude of viral infections. Both as major shareholder and a scientific partner, LifeArc continues to support and collaborate with RQ Bio so that the public health, medical and patient impact of our innovation can be maximised.
We're truly grateful to LifeArc for the belief they've shown in us as investors and the support they've been able to offer to date. Imran and his team come with a wealth of experience in the healthcare space and have been a valuable source of counsel as we shape and define company strategy at this important stage of our growth.